ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis

High-grade serous carcinoma, accounts for up to 70% of all ovarian cases. Furin, a proprotein convertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even higher in tumor omentum than in normal omentum, the preferred site of ovarian cancer met...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene Vol. 39; no. 14; pp. 2921 - 2933
Main Authors: Chen, Changliang, Gupta, Prachi, Parashar, Deepak, Nair, Gopakumar G, George, Jasmine, Geethadevi, Anjali, Wang, Wei, Tsaih, Shirng-Wern, Bradley, William, Ramchandran, Ramani, Rader, Janet S, Chaluvally-Raghavan, Pradeep, Pradeep, Sunila
Format: Journal Article
Language:English
Published: England Nature Publishing Group 02.04.2020
Subjects:
ISSN:0950-9232, 1476-5594, 1476-5594
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-grade serous carcinoma, accounts for up to 70% of all ovarian cases. Furin, a proprotein convertase, is highly expressed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even higher in tumor omentum than in normal omentum, the preferred site of ovarian cancer metastasis. The proteolytic actions of this cellular endoprotease help the maturation of several important precursors of protein substrates and its levels increase the risk of several cancer. We show that furin activates the IGF1R/STAT3 signaling axis in ovarian cancer cells. Conversely, furin knockdown downregulated IGF1R-β and p-STAT3 (Tyr705) expression. Further, silencing furin reduced tumor cell migration and invasion in vitro and tumor growth and metastasis in vivo. Collectively, our findings show that furin can be an effective therapeutic target for ovarian cancer prevention or treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0950-9232
1476-5594
1476-5594
DOI:10.1038/s41388-020-1194-7